Skip to main content

Advertisement

SpringerLink
Log in

A delicate balance: tweaking IL-2 immunotherapy

  • Community Corner
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055–2066 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Saadoun, D. et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067–2077 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. Atkins, M.B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).

    Article  CAS  PubMed  Google Scholar 

  4. Shin, H.J. et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 118, 2342–2350 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Willenbacher, W. et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br. J. Haematol. 112, 820–823 (2001).

    Article  CAS  PubMed  Google Scholar 

  6. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775–787 (2008).

    Article  CAS  PubMed  Google Scholar 

  7. Malek, T.R. & Castro, I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153–165 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rosenberg, S.A. & Lotze, M.T. Cancer immunotherapy using interleukin-2 and interleukin-2–activated lymphocytes. Annu. Rev. Immunol. 4, 681–709 (1986).

    Article  CAS  PubMed  Google Scholar 

  9. Yu, A., Zhu, L., Altman, N.H. & Malek, T.R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30, 204–217 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Webster, K.E. et al. In vivo expansion of Treg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751–760 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

A delicate balance: tweaking IL-2 immunotherapy. Nat Med 18, 208–209 (2012). https://doi.org/10.1038/nm0212-208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0212-208

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation